Hiroaki Mitsuya

List of Publications by Year
in descending order

133	5,954	81900 39	85541 71
papers	citations	h-index	g-index

145	145	145	6600
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. Journal of Virology, 2022, 96, JVI0155121.	3.4	18
2	Fluorine Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier Penetration Property of Novel Central Nervous System-Targeting HIV-1 Protease Inhibitors In Vitro. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0171521.	3.2	5
3	Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant. New England Journal of Medicine, 2022, 386, 995-998.	27.0	301
4	Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study. Clinical Infectious Diseases, 2022, 75, e683-e691.	5.8	48
5	Safety of convalescent plasma therapy for COVID-19 patients and analysis of viral kinetics: a single-center, open-label, single-arm, interventional study in Japan. GHM Open, 2022, 2, 38-43.	0.6	4
6	A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection. CEN Case Reports, 2022, , 1.	0.9	0
7	Design, Synthesis and Xâ€Ray Structural Studies of Potent HIVâ€1 Protease Inhibitors Containing Câ€4 Substituted Tricyclic Hexahydroâ€Furofuran Derivatives as P2 Ligands. ChemMedChem, 2022, 17, .	3.2	2
8	Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19. Journal of Infection and Chemotherapy, 2022, 28, 991-994.	1.7	4
9	An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine. Vaccines, 2022, 10, 563.	4.4	3
10	Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection. International Journal of Infectious Diseases, 2022, 119, 18-20.	3.3	0
11	Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan. Journal of Infection and Chemotherapy, 2022, , .	1.7	0
12	Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature, 2022, 607, 119-127.	27.8	174
13	A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT). Life, 2022, 12, 856.	2.4	4
14	Identification of a novel long-acting 4â€™-modified nucleoside reverse transcriptase inhibitor against HBV. Journal of Hepatology, 2021, 74, 1075-1086.	3.7	20
15	A small moleculeÂcompound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nature Communications, 2021, 12, 668.	12.8	126
16	Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinicalMedicine, 2021, 32, 100734.	7.1	134
17	Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma. Scientific Reports, 2021, 11, 5563.	3.3	42
18	A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies. Scientific Reports, 2021, 11, 5198.	3.3	55

#	Article	IF	Citations
19	Seroprevalence of antibodies against SARS-CoV-2 in a large national hospital and affiliated facility in Tokyo, Japan. Journal of Infection, 2021, 82, e1-e3.	3.3	22
20	Consistency of the results of rapid serological tests for SARS-CoV-2 among healthcare workers in a large national hospital in Tokyo, Japan. Global Health & Medicine, 2021, 3, 90-94.	1.4	2
21	Pharmacokinetics of 4â€²-cyano-2â€²-deoxyguanosine, a novel nucleoside analog inhibitor of the resistant hepatitis B virus, in a rat model of chronic kidney disease. Journal of Infection and Chemotherapy, 2021, 27, 702-706.	1.7	0
22	Characterization of a new SARS-CoV-2 variant that emerged in Brazil. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	63
23	Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC50) of neutralizing antibodies. Journal of Infection and Chemotherapy, 2021, 27, 1063-1067.	1.7	9
24	Seroprevalence of SARS-CoV-2 antibodies in a national hospital and affiliated facility after the second epidemic wave of Japan. Journal of Infection, 2021, 83, 237-279.	3.3	16
25	Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300. MBio, 2021, 12, e0209421.	4.1	13
26	Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structureâ€“Activity Relationship, and X-ray Structural Studies. Journal of Medicinal Chemistry, 2021, 64, 14702-14714.	6.4	55
27	Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors. Molecules, 2021, 26, 5782.	3.8	9
28	A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents inÂvitro. Cell Reports Methods, 2021, 1, 100122.	2.9	9
29	Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. Scientific Reports, 2021, 11, 22848.	3.3	57
30	Advances in Oncology in US and Japan: Focusing on Cancer and Infectious Diseases. World Journal of Oncology, 2021, 12, 183-194.	1.5	2
31	Synthesis and evaluation of the anti-hepatitis B virus activity of 4â€²-Azido-thymidine analogs and 4â€²-Azido-2â€²-deoxy-5-methylcytidine analogs: structural insights for the development of a novel anti-HBV agent. Nucleosides, Nucleotides and Nucleic Acids, 2020, 39, 518-529.	1.1	2
32	GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection. MBio, 2020, 11, .	4.1	52
33	Sustaining containment of COVID-19: global sharing for pandemic response. Global Health & Medicine, 2020, 2, 53-55.	1.4	37
34	Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16587-16595.	7.1	912
35	Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity. Scientific Reports, 2020, 10, 10664.	3.3	13
36	Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine. Scientific Reports, 2020, 10, 3021.	3.3	15

#	Article	IF	Citations
37	7-Deaza-7-fluoro modification confers on 4â€²-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety. Antiviral Research, 2020, 176, 104744.	4.1	7
38	Design, Synthesis, and X-ray Studies of Potent HIV-1 Protease Inhibitors with P2-Carboxamide Functionalities. ACS Medicinal Chemistry Letters, 2020, 11, 1965-1972.	2.8	6
39	Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies. Journal of Medicinal Chemistry, 2020, 63, 4867-4879.	6.4	19
40	Fight against COVID-19 but avoid disruption of services for other communicable diseases (CDs) and noncommunicable diseases (NCDs). Global Health & Medicine, 2020, 2, 343-345.	1.4	15
41	Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2565-2570.	2.2	10
42	Potent HIVâ€1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Proteinâ€Ligand Xâ€ray Structural Studies. ChemMedChem, 2019, 14, 1863-1872.	3.2	16
43	CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	17
44	Active-site deformation in the structure of HIV-1 RT with HBV-associated septuple amino acid substitutions rationalizes the differential susceptibility of HIV-1 and HBV against 4Ê¹-modified nucleoside RT inhibitors. Biochemical and Biophysical Research Communications, 2019, 509, 943-948.	2.1	8
45	Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	9
46	Novel Protease Inhibitors Containing C-5-Modifiedbis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2â€² Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	11
47	Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	12
48	A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance. Global Health & Medicine, 2019, 1, 36-48.	1.4	5
49	Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase Câ€“induced HIV latency reversal. Journal of Biological Chemistry, 2019, 294, 116-129.	3.4	31
50	Design of Highly Potent, Dualâ€Acting and Centralâ€Nervousâ€Systemâ€Penetrating HIVâ€1 Protease Inhibitors with Excellent Potency against Multidrugâ€Resistant HIVâ€1 Variants. ChemMedChem, 2018, 13, 803-815.	3.2	36
51	GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	8
52	Mechanism of Darunavir (DRV)â€™s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance. MBio, 2018, 9, .	4.1	36
53	HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir. Scientific Reports, 2018, 8, 1624.	3.3	15
54	Synthesis of 4â€²â€Substituted Purine 2â€²â€Deoxynucleosides and Their Activity against Human Immunodeficiency Virus Type 1 and Hepatitis B Virus. ChemistrySelect, 2018, 3, 3313-3317.	1.5	6

#	Article	IF	Citations
55	Raltegravir blocks the infectivity of red-fluorescent-protein (mCherry)-labeled HIV-1JR-FL in the setting of post-exposure prophylaxis in NOD/SCID/Jak3â^'/â^' mice transplanted with human PBMCs. Antiviral Research, 2018, 149, 78-88.	4.1	0
56	Synthesis, Anti-HBV, and Anti-HIV Activities of 3â€²-Halogenated Bis(hydroxymethyl)-cyclopentenyladenines. ACS Medicinal Chemistry Letters, 2018, 9, 1211-1216.	2.8	7
57	Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro. Frontiers in Microbiology, 2018, 9, 2022.	3.5	39
58	The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase. Cell Chemical Biology, 2018, 25, 1268-1278.e3.	5.2	20
59	Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands. European Journal of Medicinal Chemistry, 2018, 160, 171-182.	5.5	4
60	Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structureâ€“Activity Studies, Biological and X-ray Structural Analysis. Journal of Medicinal Chemistry, 2018, 61, 4561-4577.	6.4	31
61	Early phase dynamics of traceable mCherry fluorescent protein-carrying HIV-1 infection in human peripheral blood mononuclear cells-transplanted NOD/SCID/Jak3 -/- mice. Antiviral Research, 2017, 144, 83-92.	4.1	1
62	Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants. Journal of Medicinal Chemistry, 2017, 60, 4267-4278.	6.4	64
63	GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro. Scientific Reports, 2017, 7, 12235.	3.3	16
64	A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency. ELife, 2017, 6, .	6.0	44
65	A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413. Antimicrobial Agents and Chemotherapy, 2016, 60, 7046-7059.	3.2	14
66	Development and validation of a cell-based assay system to assess human immunodeficiency virus type 1 integrase multimerization. Journal of Virological Methods, 2016, 236, 196-206.	2.1	2
67	Structural basis of HIV inhibition by translocation-defective RT inhibitor 4â€²-ethynyl-2-fluoro-2â€²-deoxyadenosine (EFdA). Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9274-9279.	7.1	73
68	C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir. Journal of Virology, 2016, 90, 2180-2194.	3.4	15
69	Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells. International Journal of Oncology, 2015, 46, 963-972.	3.3	62
70	4â€²â€modified nucleoside analogs: Potent inhibitors active against entecavirâ€resistant hepatitis B virus. Hepatology, 2015, 62, 1024-1036.	7.3	43
71	A Novel Tricyclic Ligand-Containing Nonpeptidic HIV-1 Protease Inhibitor, GRL-0739, Effectively Inhibits the Replication of Multidrug-Resistant HIV-1 Variants and Has a Desirable Central Nervous System Penetration Property In Vitro. Antimicrobial Agents and Chemotherapy, 2015, 59, 2625-2635.	3.2	10
72	Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4903-4909.	2.2	26

#	Article	IF	Citations
73	Insights into the Mechanism of Inhibition of CXCR4: Identification of Piperidinylethanamine Analogs as Anti-HIV-1 Inhibitors. Antimicrobial Agents and Chemotherapy, 2015, 59, 1895-1904.	3.2	28
74	Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands. Organic and Biomolecular Chemistry, 2015, 13, 11607-11621.	2.8	10
75	Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Proteinâ€“Ligand X-ray Studies. Journal of Medicinal Chemistry, 2015, 58, 6994-7006.	6.4	13
76	Design of gemâ€Difluoroâ€bisâ€Tetrahydrofuran as P2 Ligand for HIVâ€1â€…Protease Inhibitors to Improve Brain Penetration: Synthesis, Xâ€ray Studies, and Biological Evaluation. ChemMedChem, 2015, 10, 107-115.	3.2	20
77	Delayed Emergence of HIV-1 Variants Resistant to 4â€²-Ethy Nyl-2-Fluoro-2â€²-Deoxyadenosine: Comparative Sequential Passage Study with Lamivudine, Tenofovir, Emtricitabine and BMS-986001. Antiviral Therapy, 2014, 19, 179-189.	1.0	44
78	EFdA, a Reverse Transcriptase Inhibitor, Potently Blocks HIV-1 Ex Vivo Infection of Langerhans Cells within Epithelium. Journal of Investigative Dermatology, 2014, 134, 1158-1161.	0.7	4
79	A Conserved Hydrogen-Bonding Network of P2 bis -Tetrahydrofuran-Containing HIV-1 Protease Inhibitors (PIs) with a Protease Active-Site Amino Acid Backbone Aids in Their Activity against PI-Resistant HIV. Antimicrobial Agents and Chemotherapy, 2014, 58, 3679-3688.	3.2	17
80	Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4â€²-ethynyl-2-fluoro-2â€²-deoxyadenosine (EFdA) using pre-steady-state kinetics. Antiviral Research, 2014, 106, 1-4.	4.1	16
81	Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12234-12239.	7.1	70
82	4â€²-Ethynyl-2-fluoro-2â€²-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms. Journal of Biological Chemistry, 2014, 289, 24533-24548.	3.4	80
83	Effects of Substitutions at the 4â€² and 2 Positions on the Bioactivity of 4â€²-Ethynyl-2-Fluoro-2â€²-Deoxyadenosine. Antimicrobial Agents and Chemotherapy, 2013, 57, 6254-6264.	3.2	35
84	Comparative analysis of ER stress response into HIV protease inhibitors: Lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway. Free Radical Biology and Medicine, 2013, 65, 778-788.	2.9	32
85	GRL-04810 and GRL-05010, Difluoride-Containing Nonpeptidic HIV-1 Protease Inhibitors (PIs) That Inhibit the Replication of Multi-PI-Resistant HIV-1 In Vitro and Possess Favorable Lipophilicity That May Allow Blood-Brain Barrier Penetration. Antimicrobial Agents and Chemotherapy, 2013, 57, 6110-6121.	3.2	21
86	Evaluation of Combinations of 4â€²-Ethynyl-2-Fluoro-2â€²-Deoxyadenosine with Clinically Used Antiretroviral Drugs. Antimicrobial Agents and Chemotherapy, 2013, 57, 4554-4558.	3.2	21
87	P2â€² Benzene Carboxylic Acid Moiety Is Associated with Decrease in Cellular Uptake: Evaluation of Novel Nonpeptidic HIV-1 Protease Inhibitors Containing P2 bis -Tetrahydrofuran Moiety. Antimicrobial Agents and Chemotherapy, 2013, 57, 4920-4927.	3.2	32
88	GRL-0519, a Novel Oxatricyclic Ligand-Containing Nonpeptidic HIV-1 Protease Inhibitor (PI), Potently Suppresses Replication of a Wide Spectrum of Multi-PI-Resistant HIV-1 Variants In Vitro. Antimicrobial Agents and Chemotherapy, 2013, 57, 2036-2046.	3.2	24
89	Lactate Is a Crucial Energy Source For Multiple Myeloma (MM) Cells In Bone Marrow Microenvironment. Blood, 2013, 122, 3109-3109.	1.4	2
90	Response of Simian Immunodeficiency Virus to the Novel Nucleoside Reverse Transcriptase Inhibitor 4â€²-Ethynyl-2-Fluoro-2â€²-Deoxyadenosine In Vitro and In Vivo. Antimicrobial Agents and Chemotherapy, 2012, 56, 4707-4712.	3.2	50

#	Article	IF	Citations
91	Loss of the Protease Dimerization Inhibition Activity of Tipranavir (TPV) and Its Association with the Acquisition of Resistance to TPV by HIV-1. Journal of Virology, 2012, 86, 13384-13396.	3.4	26
92	Novel HIV-1 Protease Inhibitors (PIs) Containing a Bicyclic P2 Functional Moiety, Tetrahydropyrano-Tetrahydrofuran, That Are Potent against Multi-PI-Resistant HIV-1 Variants. Antimicrobial Agents and Chemotherapy, 2011, 55, 1717-1727.	3.2	25
93	Loss of Protease Dimerization Inhibition Activity of Darunavir Is Associated with the Acquisition of Resistance to Darunavir by HIV-1. Journal of Virology, 2011, 85, 10079-10089.	3.4	40
94	Novel Protease Inhibitors (PIs) Containing Macrocyclic Components and 3(R),3a(S),6a() Tj ETQq0 0 0 rgBT /Overlock 10 Variants In Vitro. Antimicrobial Agents and Chemotherapy, 2010, 54, 3460-3470.	3.2	21
95	In Vitro Selection of Highly Darunavir-Resistant and Replication-Competent HIV-1 Variants by Using a Mixture of Clinical HIV-1 Isolates Resistant to Multiple Conventional Protease Inhibitors. Journal of Virology, 2010, 84, 11961-11969.	3.4	85
96	CD125-Expressing Myeloma: A Subgroup of Multiple Myeloma (MM) with Immature Phenotype, Endoplasmic Reticulum Stress Response and Low Sensitivity to Bortezomib. Blood, 2010, 116, 616-616.	1.4	0
97	Production of TRAIL by Multiple Myeloma Cells: a Potential Prediction Marker for Skeletal-Related Events. Blood, 2010, 116, 2975-2975.	1.4	9
98	Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4â€²-Ethynyl-2-fluoro-2â€²-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor. Journal of Biological Chemistry, 2009, 284, 35681-35691.	3.4	117
99	Non-Cleavage Site Gag Mutations in Amprenavir-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) Predispose HIV-1 to Rapid Acquisition of Amprenavir Resistance but Delay Development of Resistance to Other Protease Inhibitors. Journal of Virology, 2009, 83, 3059-3068.	3.4	27
100	Potent Activity of a Nucleoside Reverse Transcriptase Inhibitor, 4â€²-Ethynyl-2-Fluoro-2â€²-Deoxyadenosine, against Human Immunodeficiency Virus Type 1 Infection in a Model Using Human Peripheral Blood Mononuclear Cell-Transplanted NOD/SCID Janus Kinase 3 Knockout Mice. Antimicrobial Agents and Chemotherapy, 2009, 53, 3887-3893.	3.2	56
101	Development of Protease Inhibitors and the Fight with Drugâ€Resistant HIVâ€1 Variants. Advances in Pharmacology, 2008, 56, 169-197.	2.0	47
102	2â€²-Deoxy-4â€²-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. International Journal of Biochemistry and Cell Biology, 2008, 40, 2410-2420.	2.8	114
103	Conditionally Expressed PU.1 Transactivates TRAIL Gene and Induces Apoptosis in Myeloma Cell Lines.. Blood, 2008, 112, 1676-1676.	1.4	0
104	Characteristics of Chronic-Phase CML Patients Having Durable Cytogenetic Response to Low-Dose Imatinib. Blood, 2008, 112, 3218-3218.	1.4	0
105	Activity against Human Immunodeficiency Virus Type 1, Intracellular Metabolism, and Effects on Human DNA Polymerases of 4â€²-Ethynyl-2-Fluoro-2â€²-Deoxyadenosine. Antimicrobial Agents and Chemotherapy, 2007, 51, 2701-2708.	3.2	96
106	A Novel Bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI), GRL-98065, Is Potent against Multiple-PI-Resistant Human Immunodeficiency Virus In Vitro. Antimicrobial Agents and Chemotherapy, 2007, 51, 2143-2155.	3.2	66
107	Potent Inhibition of HIV-1 Replication by Novel Non-peptidyl Small Molecule Inhibitors of Protease Dimerization. Journal of Biological Chemistry, 2007, 282, 28709-28720.	3.4	137
108	Emergence of human immunodeficiency virus type 1 variants containing the Q151M complex in children receiving long-term antiretroviral chemotherapy. Antiviral Research, 2007, 75, 159-166.	4.1	10

#	Article	IF	Citations
109	Altered HIV-1 Gag Protein Interactions with Cyclophilin A (CypA) on the Acquisition of H219Q and H219P Substitutions in the CypA Binding Loop. Journal of Biological Chemistry, 2006, 281, 1241-1250.	3.4	47
110	Kigamicin Induces Necrosis to Human Myeloma Cells by Disruption of Cell Cycle Regulation.. Blood, 2006, 108, 5017-5017.	1.4	0
111	Potent Anti-R5 Human Immunodeficiency Virus Type 1 Effects of a CCR5 Antagonist, AK602/ONO4128/GW873140, in a Novel Human Peripheral Blood Mononuclear Cell Nonobese Diabetic-SCID, Interleukin-2 Receptor Î³-Chain-Knocked-Out AIDS Mouse Model. Journal of Virology, 2005, 79, 2087-2096.	3.4	59
112	Appearance of Stress-Inducible Membrane Proteins ULBP on Blood Cells of Patients with PNH, Aplastic Anemia, and MDS: Possible Implication of ULBP in Immune-Mediated Marrow Injury.. Blood, 2005, 106, 1041-1041.	1.4	0
113	Induction of Autophagy to Myeloma Cells by Thalidomide and Clarithromycin.. Blood, 2005, 106, 5134-5134.	1.4	0
114	Design, Efficient Synthesis, and Antiâ€HIV Activity of 4â€²â€Câ€Cyanoâ€•and 4â€²â€Câ€Ethynylâ€2â€²â€•deoxy Purine Nucleosides. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 671-690.	1.1	44
115	Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro. Antimicrobial Agents and Chemotherapy, 2003, 47, 3123-3129.	3.2	355
116	Amino Acid Substitutions in Gag Protein at Non-cleavage Sites Are Indispensable for the Development of a High Multitude of HIV-1 Resistance against Protease Inhibitors. Journal of Biological Chemistry, 2002, 277, 5952-5961.	3.4	143
117	A Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor, UIC-94003 (TMC-126), and Selection of a Novel (A28S) Mutation in the Protease Active Site. Journal of Virology, 2002, 76, 1349-1358.	3.4	134
118	4â€²-Ethynyl Nucleoside Analogs: Potent Inhibitors of Multidrug-Resistant Human Immunodeficiency Virus Variants In Vitro. Antimicrobial Agents and Chemotherapy, 2001, 45, 1539-1546.	3.2	137
119	Mutations in the HIV Type 1 Integrase of Patients Receiving Long-Term Dideoxynucleoside Therapy Do Not Confer Resistance to Zidovudine. AIDS Research and Human Retroviruses, 2000, 16, 1417-1422.	1.1	5
120	Identification of a Key Target Sequence To Block Human Immunodeficiency Virus Type 1 Replication within thegag-pol Transframe Domain. Journal of Virology, 2000, 74, 4621-4633.	3.4	2
121	Characterization of Human Immunodeficiency Virus Type 1 Strains Resistant to the Non-Nucleoside Reverse Transcriptase Inhibitor RD4â€“2217. Antiviral Chemistry and Chemotherapy, 1999, 10, 315-320.	0.6	6
122	Lessons from the Pseudorotational Cycle: Conformationally Rigid AZT Carbocyclic Nucleosides and Their Interaction with Reverse Transcriptase. Nucleosides & Nucleotides, 1998, 17, 1881-1884.	0.5	13
123	HIV-1 Reverse Transcriptase Can Discriminate between Two Conformationally Locked Carbocyclic AZT Triphosphate Analogues. Journal of the American Chemical Society, 1998, 120, 2780-2789.	13.7	156
124	Phosphodiester Amidates of Unsaturated Nucleoside Analogues as Anti-HIV Agents. Nucleosides & Nucleotides, 1997, 16, 1341-1345.	0.5	2
125	Comparative Enzymatic Study of HIV-1 Reverse Transcriptase Resistant to 2â€˜,3â€˜-Dideoxynucleotide Analogs Using the Single-Nucleotide Incorporation Assay. Biochemistry, 1997, 36, 1092-1099.	2.5	63
126	Human Immunodeficiency Virus Type 1 (HIV-l) Viremia Changes and Development of Drug-Related Mutations in Patients with Symptomatic HIV-l Infection Receiving Alternating or Simultaneous Zidovudine and Didanosine Therapy. Journal of Infectious Diseases, 1995, 171, 1152-1158.	4.0	47

#	Article	IF	Citations
127	Five-Year Follow-Up of a Phase I Study of Didanosine in Patients with Advanced Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 1995, 171, 1180-1189.	4.0	23
128	Current Status of the Development of HIV Protease Inhibitors and Their Clinical Potential. BioDrugs, 1995, 4, 451-461.	0.7	7
129	Development of Inhibitors of Reverse Transcriptase and Protease as Therapeutics Against HIV Infection. Journal of Enzyme Inhibition and Medicinal Chemistry, 1992, 6, 1-8.	0.5	5
130	Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV. Journal of Medicinal Chemistry, 1990, 33, 978-985.	6.4	224
131	Inhibition of duck hepatitis B virus replication by 2â€²,3â€²-dideoxycytidine. Gastroenterology, 1989, 97, 1275-1280.	1.3	67
132	Proliferative responsiveness of B cells in primary immunodeficiency. Japanese Journal of Clinical Immunology, 1983, 6, 102-109.	0.0	0
133	Effect of streptococcal preparation, OK-432 on cultured spontaneous cell mediated cytotoxicity (CSCMC) and Ig production <i>in vitro</i>. Japanese Journal of Clinical Immunology, 1981, 4, 312-321.	0.0	1